← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 Kyverna Therapeutics KYTX $365M	–	–	–	–
102	102 Legend Biotech LEGN $3.83B	–	–	–	–
103	LGVN 103 Longeveron LGVN $5.1M	–	–	–	–
104	104 Lexeo Therapeutics LXEO $229M	–	–	–	–
105	105 Lyell Immunopharma LYEL $195M	–	–	–	–
106	106 Metagenomi Therapeutics MGX $32.9M	–	–	–	–
107	107 NewcelX Ltd NCEL $15.3M	–	–	–	–
108	108 DELISTED NKGen Biotech, Inc. Common Stock NKGN	–	–	–	–
109	109 Nkarta NKTX $143M	–	–	–	–
110	OBX 110 Obsidian Therapeutics OBX $763M	–	–	–	–
111	111 Passage Bio PASG $11.8M	–	–	–	–
112	112 PharmaCyte Biotech PMCB $3.81M	–	–	–	–
113	113 Prime Medicine PRME $624M	–	–	–	–
114	114 ProKidney PROK $307M	–	–	–	–
115	115 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
116	RCOR 116 DELISTED Renovacor, Inc. RCOR	–	–	–	–
117	117 Sana Biotechnology SANA $736M	–	–	–	–
118	SCPS 118 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
119	SCTX 119 Scribe Therapeutics Inc SCTX $385M	–	–	–	–
120	SGTX 120 DELISTED Sigilon Therapeutics, Inc. Common Stock SGTX	–	–	–	–
121	SLBT 121 SL Science Holding Ltd SLBT $886M	–	–	–	–
122	122 Senti Biosciences Holdings SNTI $7.62M	–	–	–	–
123	SQZ 123 DELISTED SQZ Biotechnologies Company SQZ	–	–	–	–
124	TCBP 124 DELISTED TC BioPharm (Holdings) plc American Depositary Shares TCBP	–	–	–	–
125	TCRR 125 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	–	–	–	–